Madrigal Pharmaceuticals, Inc.
MDGL
$-1.49
Change (1 day)
$368.29
Year High
$168.25
Year Low
Categories
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Madrigal Pharmaceuticals, Inc. (MDGL) - Company Outlook
Company Outlook
| Year | Receivables | Debt | Liabilities | Assets | Current Assets |
|---|---|---|---|---|---|
| 2023 | 17.28 M | 235.21 M | 640.55 M | 637.28 M | |
| 2022 | -281,658,000 | 165.18 M | 362.57 M | 361.37 M | |
| 2021 | -35,472,000 | 77.23 M | 273.33 M | 271.68 M | |
| 2020 | -53,218,000 | 47.03 M | 287 M | 285.16 M | |
| 2019 | -46,021,000 | 25.49 M | 442.06 M | 440.2 M |